# Prolonged Clinical Follow-up of OPTIMA-5

> **NCT05649696** · PHASE4 · COMPLETED · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 210 (actual)

## Conditions studied

- ST-segment Elevation Myocardial Infarction (STEMI)

## Interventions

- **DRUG:** Recombinant Staphylokinase
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT05649696
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-29
- **Primary completion:** 2023-09-14
- **Final completion:** 2023-10-01
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05649696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05649696, "Prolonged Clinical Follow-up of OPTIMA-5". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05649696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*